Clinical and urodynamic effects of norfenefrine in women with stress incontinence

Urol Int. 1984;39(5):298-302. doi: 10.1159/000280997.

Abstract

20 women with stress incontinence were treated with an alpha-adrenoceptor stimulating agent norfenefrine (Nevadral Retard) for 3 months. The mean dose administered was 60 mg given in slow-release tablets. Significant beneficial effect on the symptom and the 'sign' of stress incontinence was found as well as a significant increase in the maximum urethral closure pressure. 7 patients (35%) became subjectively and objectively continent. Only minor side effects were observed during treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Hydroxyphenethylamine / administration & dosage
  • 2-Hydroxyphenethylamine / adverse effects
  • 2-Hydroxyphenethylamine / analogs & derivatives
  • 2-Hydroxyphenethylamine / therapeutic use*
  • Adrenergic alpha-Agonists / therapeutic use*
  • Adult
  • Aged
  • Delayed-Action Preparations
  • Female
  • Humans
  • Male
  • Middle Aged
  • Octopamine* / analogs & derivatives*
  • Phenethylamines / therapeutic use*
  • Urethra / physiopathology
  • Urinary Incontinence, Stress / drug therapy*
  • Urinary Incontinence, Stress / physiopathology
  • Urodynamics

Substances

  • Adrenergic alpha-Agonists
  • Delayed-Action Preparations
  • Phenethylamines
  • Octopamine
  • 2-Hydroxyphenethylamine
  • norfenefrine